Findings

What do systematic reviews say?

7 questions · 7 findings · 4 reviews · Urology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 28.6%Moderate 4 · 57.1%High 1 · 14.3%

Combination therapy vs anticholinergics

Adverse events · men with lower urinary tract symptoms secondary to benign prostatic obstruction

Combination therapy showed no clear difference in adverse events compared with anticholinergics (moderate certainty).

1 finding from 1 review

Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic… 2021 · Cochrane Headline outcomes only
RR 1.26 [0.81, 1.95]
1 study · 661 participants
Moderate

Combination therapy vs placebo

Adverse events · men with lower urinary tract symptoms secondary to benign prostatic obstruction

Combination therapy probably leads to higher adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic… 2021 · Cochrane Headline outcomes only
RR 1.24 [1.04, 1.47]
3 studies · 1848 participants
Moderate

Combination therapy vs alpha‐blocker

Adverse events · men with lower urinary tract symptoms secondary to benign prostatic obstruction

Combination therapy showed no clear difference in adverse events compared with alpha‐blockers (low certainty).

1 finding from 1 review

Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic… 2021 · Cochrane Headline outcomes only
RR 1.1 [0.9, 1.34]
12 studies · 3561 participants
Low

Serenoa repens in combination with other phytotherapy vs placebo or no intervention

Adverse eventsCumulative incidence · men with lower urinary tract symptoms secondary to benign prostatic obstruction

Serenoa repens in combination with other phytotherapy showed no clear difference in adverse eventsCumulative incidence compared with placebo or no intervention (low certainty).

1 finding from 1 review

Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement 2023 · Cochrane Headline outcomes only
RR 0.91 [0.58, 1.41]
4 studies · 481 participants
Low

Sunitinib vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only.

Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with nivolumab + ipilimumab (targeted agent versus combinations of… (moderate certainty).

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
RR 1.37 [1.22, 1.53]
1 study · 1082 participants
Moderate

Abiraterone + ADT vs ADT only

Discontinued treatment due to adverse events measured at a median · men with metastatic, hormone‐sensitive prostate cancer

Abiraterone + ADT probably leads to higher discontinued treatment due to adverse events measured at a median compared with ADT alone (moderate certainty).

1 finding from 1 review

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for… 2020 · Cochrane Headline outcomes only
RR 1.5 [1.17, 1.92]
1 study · 1199 participants
Moderate

Abiraterone + ADT vs ADT only

Adverse events grade 3 to 5 Range of · men with metastatic, hormone‐sensitive prostate cancer

Abiraterone + ADT leads to higher grades III to V adverse events (severe and life threatening, as per… compared with ADT alone (high certainty).

1 finding from 1 review

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for… 2020 · Cochrane Headline outcomes only
RR 1.34 [1.22, 1.47]
1 study · 1199 participants
High